122 related articles for article (PubMed ID: 14637122)
1. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration.
Double KL; Halliday GM; Henderson J; Griffiths FM; Heinemann T; Riederer P; Gerlach M
Exp Neurol; 2003 Nov; 184(1):530-5. PubMed ID: 14637122
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
4. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
5. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Li X; Matsumoto K; Murakami Y; Tezuka Y; Wu Y; Kadota S
Pharmacol Biochem Behav; 2005 Oct; 82(2):345-52. PubMed ID: 16214209
[TBL] [Abstract][Full Text] [Related]
7. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
[TBL] [Abstract][Full Text] [Related]
8. The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat.
Caldwell MA; Reymann JM; Bentue-Ferrer D; Allain H; Leonard BE
Neuropsychobiology; 1996; 34(3):117-24. PubMed ID: 8916068
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.
Liu M; Bachstetter AD; Cass WA; Lifshitz J; Bing G
J Neurotrauma; 2017 Jan; 34(2):414-422. PubMed ID: 27142118
[TBL] [Abstract][Full Text] [Related]
11. Effects of a unilateral stereotaxic injection of Tinuvin 123 into the substantia nigra on the nigrostriatal dopaminergic pathway in the rat.
Jackson-Lewis V; Liberatore G
Brain Res; 2000 Jun; 866(1-2):197-210. PubMed ID: 10825495
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone.
Antkiewicz-Michaluk L; Wardas J; Michaluk J; Romaska I; Bojarski A; Vetulani J
Int J Neuropsychopharmacol; 2004 Jun; 7(2):155-63. PubMed ID: 14741061
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
15. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D3 receptor-modulated neuroprotective effects of lisuride.
Kim M; Lee S; Cho J; Kim G; Won C
Neuropharmacology; 2017 May; 117():14-20. PubMed ID: 28131770
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
19. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Vu TQ; Ling ZD; Ma SY; Robie HC; Tong CW; Chen EY; Lipton JW; Carvey PM
J Neural Transm (Vienna); 2000; 107(2):159-76. PubMed ID: 10847557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
